MAPT and Alzheimer disease: Similarly, pharmacological inhibition of LIMK1 has been shown to provide dendritic spine resilience against amyloid-β (Aβ) protein, the main constituent of amyloid plaques and one of the core hallmarks of AD, together with neurofibrillary tangle accumulation, consisting of hyperphosphorylated tau protein [18].